Previous 10 | Next 10 |
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis PR Newswire SAN DIEGO , May 22, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advanci...
2023-05-19 17:30:11 ET Gainers: WISeKey International Holding ( WKEY ) +6% . Viracta Therapeutics ( VIRX ) +5% . Fossil Group ( FOSL ) +5% . OmniAb ( OABI ) +5% . Lifecore Biomedical ( LFCR ) +4% . Losers: Jupiter Wellnes...
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting PR Newswire Six presentations highlight significant advancements across the Company's Gene Therapy platform ...
2023-05-09 17:55:30 ET Poseida Therapeutics press release ( NASDAQ: PSTX ): Q1 GAAP EPS of -$0.45 misses by $0.03 . Revenue of $10.34M (+618.1% Y/Y). For further details see: Poseida Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $10.34M
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023 PR Newswire Highlighted significant research, preclinical advances and platform technology progress at third annual R&D Day Appointed Kristin Yarema , Ph.D., as President,...
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting PR Newswire SAN DIEGO , May 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy compan...
Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference PR Newswire SAN DIEGO , May 1, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pa...
2023-04-25 08:35:07 ET Summary Updated results from phase 1 studies, using P-MUC1C-ALLO1 for epithelial cancers and P-BCMA-ALLO1 for multiple myeloma, are expected at upcoming medical conference in 2023. Partnership with Roche to advance several allogeneic CAR-T cell therapies; Po...
2023-04-24 14:19:46 ET Summary Poseida Therapeutics is developing cell and gene therapies for cancer and rare diseases, with a focus on solid tumor cell therapy. The company's lead product candidate, P-MUC1C-ALLO1, is in a Phase 1 trial for treating various solid tumors, including...
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors PR Newswire SAN DIEGO , April 13, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pat...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Inc. Website:
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum PR Newswire SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advanci...
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...